Indivior to Participate in Conference

RNS Number : 5986Q

Indivior PLC

21 February 2023

 

Indivior to Participate in Upcoming Credit Suisse 2023 Global Healthcare Conference

Slough, UK, and Richmond, VA, February 21, 2023 - Indivior PLC (LSE: INDV) today announced that Mark Crossley, Chief Executive Officer, and Ryan Preblick, Chief Financial Officer, will participate in the Credit Suisse 2023 Global Healthcare Conference in London.  Mr. Crossley and Mr. Preblick will host 1:1 and group meetings February 28^th. 

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in 39 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.

Contact:

Jason Thompson

Vice President, Investor Relations

Tel: [phone] or [e-mail]

Tim Owens

Director, Investor Relations

Tel: [phone] or [e-mail]

###

 

END

 

 

MSCEAAAFAFLDEFA